Convert Pharmaceuticals has shared the first clinical results for CP-506, its lead drug candidate. The data come from the ongoing Phase I TUMAGNOSTIC trial (NCT04954599). They show that CP-506 is well tolerated and can shrink tumours in patients who had no treatment options left. CP-506 is...
Convert Pharmaceuticals’ EIC Accelerator project, TUMAGNOSTIC, formally concluded at the end of December 2025. Supported by the European Innovation Council, the project enabled Convert to advance its lead clinical candidate, CP-506, from preclinical development into clinical evaluation. CP-506 is a hypoxia-activated prodrug designed to selectively target...
In this news, we would like to break down how hypoxia fuels cancer, why past attempts to target it failed, and how we’re working to turn hypoxia into a weapon against itself. Part 1: Tumor Hypoxia – The "Stealth Mode" of Cancer Tumor hypoxia refers to low...
Convert Pharmaceuticals has achieved a major milestone by securing the maximum €2.5 million non-dilutive grant from the prestigious European Innovation Council (EIC) Accelerator program. This competitive funding, awarded by a panel of experts, highlights the company's innovative potential and supports its ongoing Series A investment...
Yale School of Medicine's Latest Validation on Advancing Cancer Treatment Through Hypoxia-Targeted Therapies Supports Convert Pharmaceuticals' Strategy Their recent findings supported by research professionals at AstraZeneca, Johnson & Johnson, and others published in the Journal of Experimental Medicine, provide critical insights into the role of tumor...
Convert Pharmaceuticals, a leader in developing innovative therapies for treatment-resistant cancers, is pleased to announce its recent achievement of being awarded the prestigious and highly competitive EIC Accelerator grant under Horizon Europe. Convert Pharmaceuticals has earned a reputation for its groundbreaking work in developing Hypoxia-Activated Prodrugs (HAPs)...
Several academic centers have collaborated with Convert Pharmaceuticals to expand knowledge about its main compound, CP-506, and the biomarkers that will enable selection of patients that would most benefit from the hypoxia activated prodrug under investigation. These research efforts have recently led to three key...
We are glad to share that the Clinical Trial Application prepared by Convert Pharmaceuticals for the Phase 1 Clinical Trial of CP-506 (NCT04954599) has been approved by both the Competent Authorities and the reference Ethical Committee in the Netherlands. The prodrug will be tested in...
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase...